Baxter expands US portfolio with new injectables

Betsy Goodfellow | April 12, 2024 | News story | Medical Communications Pharmacy, baxter, injectables, product launch 

Baxter International has announced the continued expansion of its pharmaceuticals portfolio with the launch of five new injectable products in the US.

The products covered in this launch include:

  • Norepinephrine Bitartrate in 5% Dextrose injection in a new 16mg/250ml strength, indicated to raise blood pressure in adult patients who have severe, acute hypotension
  • Vasopressin in 0.9% Sodium Chloride Injection, the first and only US Food and Drug Administration (FDA)-approved ready-to-use Vasopressin in a flexible container, indicated to increase blood pressure in adult patients with vasodilatory shock who are still hypotensive despite fluids and catecholamines
  • Vancomycin Injection, USP in 5% Dextrose in new 1.25g/250ml and 1.15g/300ml strengths, indicated for serious or severe infections caused by certain strains of methicillin-resistant staphylococci
  • Ropivacaine Hydrochloride Injection, USP in a ready-to-use, single-dose infusion bag, indicated to produce local or regional anaesthesia for surgery and acute pain management
  • Regadenoson Injection in a pre-filled syringe, a coronary vasodilator often used for pharmacologic stress testing.

Alok Sonig, executive vice president and group president of Pharmaceuticals at Baxter, commented: “These launches demonstrate Baxter’s focus on differentiated products that address unmet patient needs in key therapeutic areas, including anti-infective and anti-hypotensive medications. We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”

Betsy Goodfellow

Related Content

ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment

ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, …

baxter

Baxter partners up with Mayo Clinic for new “centre of exellence” in renal care

American pharma firm Baxter has announced a new partnership with the Mayo Clinic in a …

injection-519388_960_720

Injectable drug market to grow to $625 billion worldwide by 2021

New data released by intelligence firm MarketsandMarkets indicates that the global injectable drug market is …

Latest content